Skip to main content
. Author manuscript; available in PMC: 2008 Oct 8.
Published in final edited form as: Cancer Cell. 2007 May;11(5):395–406. doi: 10.1016/j.ccr.2007.02.025

Figure 2. Rosiglitazone and Carboplatin Synergize to Suppress Growth in Multiple Cell Types.

Figure 2

Cells were treated with the indicated concentrations of carboplatin and 0.5 μM rosiglitazone or (B) 0.2 μM rosiglitazone. (A and B) NSCLC adenocarcinoma, (C) squamous cell carcinoma, (D) adenosquamous cell carcinoma, (E) OVCA420, or (F) OVCA429 ovarian epithelial cancer cell lines were treated with 1 μM rosiglitazone and 10 μM carboplatin alone or in combination. Cell number was determined after 7–10 days and expressed as a percent of control cells. Representative experiments, n = 3 mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.